Mariano Provencio: Perioperative chemotherapy and nivolumab in NSCLC

Mariano Provencio, Medical Oncology Chair at University Hospital Puerta de Hierro, shared on X:

”With NADIM at Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón), we were disruptive. We had to overcome skepticism to break the standard.

Today, 5 years later, The Lancet Oncology confirms the robustness of our strategy. 69% alive at 5Y, without severe toxicities. Congratulations.”

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra-Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna-Blasco, Atocha Romero, Alberto Cruz-Bermúdez.